Luke Miels, GSK chief commercial officer

GSK picks up Scynex­is' FDA-ap­proved an­ti­fun­gal drug for $90M up­front

GSK is dish­ing out $90 mil­lion cash to add an an­ti­fun­gal drug to its com­mer­cial port­fo­lio, in a deal spot­light­ing the phar­ma gi­ant’s grow­ing fo­cus …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.